Flex­ion nabs FDA OK for its po­ten­tial block­buster os­teoarthri­tis drug, trig­ger­ing new buy­out buzz

The buy­out buzz around Flex­ion $FLXN is spik­ing this week­end, af­ter the FDA came through with an ap­proval of its in­jectable drug for os­teoarthri­tis-re­lat­ed knee pain.

The agency’s OK of Zil­ret­ta in­tro­duces a new pain ther­a­py at a time the feds are bend­ing over back­wards to fight a na­tion­wide opi­oid cri­sis. And at about $500 a shot, RBC — which is push­ing up the odds of an ac­qui­si­tion again — had mod­eled peak sales at just over the $1 bil­lion-a-year mark, which would qual­i­fy as a hot­ly sought af­ter block­buster.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER